NOT-CA-24-052: Notice of Information: Reissuance of Notices of Funding Opportunity (NOFO) Dissemination and Implementation Research in Health (R01, R21, R03)

Notice of Information: Reissuance of Notices of Funding Opportunity (NOFO) “Dissemination and Implementation Research in Health” (R01, R21, R03)

Notice Number:

NOT-CA-24-052

Key Dates

Release Date:

July 17, 2024

Related Announcements

May 09, 2022 - Dissemination and Implementation Research in Health (R01 Clinical Trial Optional). See NOFO PAR-22-105
May 09, 2022 - Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed). See NOFO PAR-22-106
May 09, 2022 - Dissemination and Implementation Research in Health (R21 Clinical Trial Optional). See NOFO PAR-22-109

Issued by

National Cancer Institute (NCI)

Purpose

This Notice is to inform the research community that the National Cancer Institute (NCI) intends to reissue the Notices of Funding Opportunities (NOFOs) to solicit applications for dissemination and implementation research in health (DIRH).

These NOFOs are intended to be reissuances of PAR-22-105 (R01 Clinical Trial Optional), PAR-22-106 (R03 Clinical Trial Not Allowed), and PAR-22-109 (R01 Clinical Trial Optional), which are scheduled to expire on May 08, 2025. All participating NIH institutes, centers, and offices will be clearly identified and designated on the published NOFOs.

These reissued NOFOs will be published on November 6, 2024 to ensure compliance with the new Simplified Review Framework (see NOT-OD-24-010) for applications submitted on or after January 25, 2025. Thus, the DIRH Program will continue without interruption and grant applications will be accepted on Standard Application Due date(s) beginning on February 5, 2025, and thereafter.

The reissued NOFOs will be accompanied by a Notice of Early Expiration for PAR-22-105 (R01 Clinical Trial Optional), PAR-22-106 (R03 Clinical Trial Not Allowed), and PAR-22-109 (R01 Clinical Trial Optional). The new expiration date will be January 08, 2025. This will ensure that all applications are submitted to the reissued NOFOs and in compliance with the new Simplified Review Framework policies.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. It is also being provided to ensure that applicants are aware of the anticipated change in the expiration date for the existing NOFOs and to ensure that applicants apply to the reissued NOFOs for the February 2025 due dates.

Inquiries

Please direct all inquiries to:

Gila Neta, PhD
National Cancer Institute (NCI)
Telephone: 240-276-6785
Email: [email protected]